Quantcast
Channel: Latest Crohn's Disease News on BioPortfolio
Viewing all articles
Browse latest Browse all 2985

Kezar Life Sciences Announces Initiation of Phase 1 Clinical Program for Lead Candidate KZR616 a FirstinClass Immunoproteasome Inhibitor

$
0
0
SOUTH SAN FRANCISCO Calif. Sept. 13 2016 PRNewswire &160;Kezar Life Sciences a company focused on the discovery and development of drugs targeting protein homeostasis announced today the initiation of its Phase 1 randomized doubleblind clinical program...

Viewing all articles
Browse latest Browse all 2985

Trending Articles